LifeSignals receives CE Mark Approval for LifeSignals LX1550E Multiparameter Remote Monitoring Platform

What Kind of Equipment is Used to Analyze DNA?

Below are some of a few basic processes followed throughout DNA testing. The general procedure entails:  • Isolating DNA from a sample containing the needed...

mJOULE Launches in the United Kingdom Reports Sciton

"Sciton is dedicated to worldwide support and growth. We continue to demonstrate our commitment to developing high quality devices and marketing efforts for our physician and medspa partners worldwide." says Lacee J. Naik, Vice President of Marketing and Public Relations.

FDA Issues Draft Guidance on Remanufacturing and Discussion Paper Seeking Feedback on Cybersecurity Servicing of Medical Devices

With this in mind, the FDA is issuing today's draft guidance to help clarify whether activities performed on medical devices are likely remanufacturing as well as a discussion paper on cybersecurity servicing of devices.

LifeSignals Inc., today announced the CE (Conformité Européene) Mark for the LifeSignals LX1550E Multiparameter Remote Monitoring Platform – which can be used by clinicians for the continuous collection of physiological data of patients at home and in healthcare settings.

The single-use, wearable medical biosensor, records Electrocardiography (2-channel ECG), Heart Rate, Respiration rate, Skin Temperature and Body Posture data for up to five days. The encrypted physiological data can then be transmitted with high reliability from the LifeSignals Biosensor, via the Relay App to a secure cloud-based platform. Clinicians and Care Providers can access the cloud-based LifeSignals Remote Monitoring Dashboard to view patient physiological data and manage vital sign alert settings.

The LifeSignals Remote Monitoring Platform is designed to enable healthtech companies to rapidly enhance their product and service portfolios to provide vital sign monitoring to the widest possible patient base, from any location. The interoperable platform can be tailored with ready-to-deploy software development kit APIs and is suitable for large scale implementation.

“COVID-19 has accelerated the adoption of remote patient monitoring globally,” says Steve Jones, Business Development Director, Europe. “This regulatory approval for our Multiparameter Platform is a significant breakthrough and will enable our Partners to bring to market affordable and scalable remote monitoring products and solutions”.

spot_img

DON'T MISS

Hyperfine Adds Medtech Leader and Visionary Scott Huennekens as Executive Chairman

Mr. Huennekens’ public boards include Chairman of Acutus Medical (IPO August 2020); Chairman of Envista (IPO September 2019); and board member of Nuvasive. He also serves as a board member and past Chairman of the Medical Device Manufacturer’s Association (MDMA).

One Drop Reports Carrie Siragusa, CPA Appointed VP of Commercial Strategy, Biosensor

Formerly Head of Innovation and Diabetes Portfolio at Sanofi, Siragusa will be part of a team bringing a multi-analyte dermal sensor (biosensor) with continuous health sensing capabilities to market with a mission to provide broader access to continuous glucose monitoring.

Barbara Moorhouse Appointed as Medica Non-Executive Director

Barbara has extensive business and management experience in the private, public, and regulated sectors.

Subscribe to Medical Device News Magazine here.

Related Articles